Those in the electronic frequency research mentoring program need to (1) follow updates in the medical literature, (2) develop hypotheses of health problem causation, (3) develop frequency sets to test these hypothesis, (4) confirm that individuals with health problems respond to these frequency sets, and (5) repeatedly prevent or eliminate these health problems by providing solutions.
Let’s consider the state of research in heart disease, particularly atherosclerosis. Leading researchers now assume this is caused by inflammation. That means there is likely to be a pathogen that causes inflammation and the health problem could be prevented by eliminating the pathogen.
Exercise 1: What is the pathogen?
Exercise 2: What is its frequency?
Hint: New Scientist reported this week that vaccination with oxidized LDL reduces the incidence of artherosclerotic plaque formation in mice by 70%. You don’t have to be a rocket scientist to conclude that there is a pathogen in cells with oxidized LDL and that it could be eliminated by applying correct frequencies. Those who have studied the vaccination problem carefully know that it is a shock to the immune system with potential negative side effects. Developing easy means to kill the pathogen is more effective and avoids compromising the immune system. This should intensify research to identify the pathogen and find frequencies that easily exterminate it. Success in doing this puts you at least two steps ahead of conventional approaches to the problem. Since a single step in medicine requires an average of 17 years from publication to routine treatment, you will be 2×17 or 34 years ahead of the conventional paradigm if you can finish these exercises.
Vaccination could protect against heart disease
James Randerson, New Scientist, 22 December 2004
About 10 years ago, Jan Nilsson at Lund University in Sweden tried to provoke this immune response by giving oxidised LDL to mice. Oxidised LDL is the main form of the protein found in plaques, so Nilsson expected to see more atherosclerosis. But he was wrong. “To our surprise the mice were protected,” he says.
This started him thinking that patients could be vaccinated against atherosclerosis, an idea that his group and Hansson’s group have been working on independently. Both teams are using fragments of the oxidised form of LDL to prime the immune system to attack plaques when they first begin to form.
To test the idea, they have been injecting groups of mice with LDL fragments or a saline control. The mice given the LDL vaccination show as much as a 70% reduction in the number of plaques, and existing plaques appeared to stop growing, Nilsson and Hansson reported at the Cambridge meeting. There were no signs of any ill effects.
Libby, Peter. Atherosclerosis: The New View. Scientific American, May 2002, pp. 47-55.
PETER LIBBY, who earned his M.D. from the University of California, San Diego, is chief of cardiovascular medicine at Brigham and Women’s Hospital, Mallinckrodt Professor of Medicine at Harvard Medical School, and co-editor of the sixth edition of Heart Disease, a classic cardiology textbook (see “More to Explore,” on page 55). He regards “lifestyle modification as the cornerstone of cardiovascular prevention” and practices what he preaches by running recreationally, albeit, he says, more avidly than swiftly.
Scientists now agree that inflammation fuels the development and progression of atherosclerosis: the dangerous accumulation of fat-laden deposits, or plaques, in the arteries. The old view that fat builds up on passive artery walls is no longer tenable.
Inflammation can also cause certain plaques to rupture. Blood clots tend to form over ruptured plaques and can then occlude arteries, leading to such atherosclerotic complications as heart attack and stroke.
Excess low-density lipoprotein (LDL), or bad cholesterol, in the blood can trigger arterial inflammation. And cholesterol-lowering therapies already cornerstones of treatment for atherosclerosis can reduce it. Strategies that interfere with inflammation in other ways are under study as well.
A blood test that detects ongoing inflammation might prove useful as an adjunct to the cholesterol tests that doctors now employ to assess risk for heart attack and stroke.